| Document |
Document Title |
|
WO/2021/245051A1 |
The present invention encompasses compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, p...
|
|
WO/2021/240352A1 |
The present invention relates to a pharmaceutical formulations and compositions comprising cholinergic agonist agents such as pilocarpine-R-(+)-lipoate or its salt, solvate, or hydrate thereof for oral administration with improved compli...
|
|
WO/2021/237309A1 |
This invention relates to multi-stimuli responsive metal-organic frameworks (MOFs) comprising a repeat unit of the formula M2(L1)2(L2)2. Also disclosed are methods of preparation of multi-stimuli responsive MOFs of the formula M2(L1)2(L2...
|
|
WO/2021/236401A1 |
Invented are compounds of formula I and the pharmaceutically acceptable salts thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I,...
|
|
WO/2021/235830A1 |
The present invention provides a novel compound, and an organic light-emitting element comprising same.
|
|
WO/2021/235546A1 |
The fluorenylidene-acridane derivative has a structure represented by formula (1) (where at least one among R1-R16 is an organic group, the remainder being hydrogen atoms or organic groups, and R17 is a hydrogen atom or an organic group).
|
|
WO/2021/229244A1 |
There is provided a new process for the synthesis of compounds of formula I, which are useful as angiotensin (Ang II) type 2 receptor agonists: by reacting a compound of formula II,with an excess of a compound of formula III, wherein W, ...
|
|
WO/2021/230689A1 |
The present invention provides a novel compound, and an organic light-emitting element comprising same.
|
|
WO/2021/231553A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine or piperidine structure which function as inhibitors of the CaV3.2 voltage gated calcium ch...
|
|
WO/2021/230653A1 |
The present invention relates to: an anthracene derivative compound having a specific structure; and an organic light-emitting device having low-voltage driving characteristics, comprising same, and also relates to an organic light-emitt...
|
|
WO/2021/230690A1 |
The present invention provides a novel compound, and an organic light-emitting element comprising same.
|
|
WO/2021/230654A1 |
The present invention provides a novel compound, and an organic light-emitting element comprising same.
|
|
WO/2021/230142A1 |
A compound indicated by formula (1) (L1 is a single-bonded or unsubstituted arylene group having 6–50 ring-forming carbon atoms and Ar1 is a substituted or unsubstituted aryl group having 6–50 ring-forming carbon atoms.)
|
|
WO/2021/230655A1 |
The present invention provides a novel compound, and an organic light-emitting element comprising same.
|
|
WO/2021/231565A1 |
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, amon...
|
|
WO/2021/228111A1 |
The present application relates to the technical field of organic materials, and relates to an organic compound, and an electronic element and an electronic device using same. The organic compound has the structure as shown in formula I ...
|
|
WO/2021/230688A1 |
The present invention provides a novel compound, and an organic light-emitting element comprising same.
|
|
WO/2021/228734A1 |
The present disclosure relates to triazine and pyrimidine (thio)amide compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
|
WO/2021/224927A1 |
The invention in some embodiments thereof, relates to the field of compositions and/or pharmaceutical compositions comprising one or more biologically active compound, and is directed to methods of using same such as for treating an ApoL...
|
|
WO/2021/224220A1 |
The present disclosure relates to pyridine (thio)amide compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
|
WO/2021/224864A1 |
The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
|
|
WO/2021/225969A1 |
The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disc...
|
|
WO/2021/226003A1 |
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related disea...
|
|
WO/2021/224865A1 |
The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
|
|
WO/2021/219775A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2021/222858A1 |
Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the tre...
|
|
WO/2021/218588A1 |
The present application belongs to the field of organic light-emitting materials, and specifically relates to a nitrogen-containing compound, an electronic component using same and an electronic device. The nitrogen-containing compound h...
|
|
WO/2021/219849A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.
|
|
WO/2021/221108A1 |
The present invention provides: a photoelectric conversion element having excellent sensitivity; an imaging element, an optical sensor; and a compound. This photoelectric conversion element comprises, in the given order, an electroconduc...
|
|
WO/2021/218491A1 |
Provided are a nitrogen-containing compound, an electronic element, and an electronic device, and the present application belongs to the technical field of organic materials. The structure of the nitrogen-containing compound is as shown ...
|
|
WO/2021/212740A1 |
A class of compounds having an indoline skeleton, a preparation method and a medical use thereof. The provided compounds containing an indoline skeleton can interfere with Keap1-Nrf2 interaction, activate Nrf2 and downstream factors, red...
|
|
WO/2021/216949A1 |
Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceu...
|
|
WO/2021/213518A1 |
The present invention relates to the field of biomedicine, and specifically relates to an "LC3 binding portion-lipid droplet binding portion-conjugate" formed by means of covalently linking a structure capable of binding LC3 and a struct...
|
|
WO/2021/213521A1 |
Provided are a compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a use thereof in preparing a drug for diseases mediated by CBP and/or EP300.
|
|
WO/2021/215742A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2021/215537A1 |
The present invention addresses the problem of providing a 2-heteroarylaminoquinazolinone derivative. The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [in the formula, X1 ...
|
|
WO/2021/216642A1 |
The present disclosure provides, in part, pyrazole carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
|
|
WO/2021/215782A1 |
The present invention relates to a novel organic light-emitting compound and an organic electroluminescent device using same and, more specifically, to: a compound having excellent thermal stability, electrochemical stability, light-emit...
|
|
WO/2020/248075A9 |
The current application relates to pyronaridine or 6-chloro-2-methoxyacridine analogs having binding affinity for the ERCC1-XPF hetero-dimerization interface. The compounds can be used for targeting DNA repair in tumor cells via ERCC1-XP...
|
|
WO/2021/209383A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to meth...
|
|
WO/2021/206504A1 |
The present invention provides an organic light-emitting device.
|
|
WO/2021/207469A1 |
Embodiments of the present disclosure pertain to compositions that include a compound that inhibits the histone acetyl transferase activity of a protein, such as p300 and/or CBP. Further embodiments of the present disclosure pertain to m...
|
|
WO/2021/204197A1 |
The present invention relates to the technical field of biological medicines, and provides an application of an acridinedione compound in preparation of anti-diabetic drugs. The present invention is the first to demonstrate that the acri...
|
|
WO/2021/203673A1 |
The present application provides a nitrogen containing compound, an organic electroluminescent device using same, and an electronic device. A chemical structure of an organic compound in the present invention comprises a carbazole ring. ...
|
|
WO/2021/206305A1 |
The present invention provides: a compound represented by Chemical Formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electr...
|
|
WO/2021/206488A1 |
The present invention relates to an anthracene compound represented by [Formula A] and an organic light-emitting element comprising same, wherein [Formula A] is as described in the detailed description of the invention.
|
|
WO/2021/200934A1 |
The present invention provides a compound indicated by formula (I) or a salt thereof that is useful for the prevention or treatment of malaria (in the formula, each of the symbols is as defined in the specification).
|
|
WO/2021/203023A1 |
Indole derivatives as alpha-l-antitrypsin modulators for treating alpha-l-antitrypsin deficiency (AATD).
|
|
WO/2021/203131A1 |
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
|
|
WO/2021/203001A1 |
The present disclosure provides methods, pharmaceutical compositions, and kits for therapeutically or prophylactically treating a subject suffering from a viral infection. The method comprises administering to the subject a therapeutical...
|
